News
GlobalData on MSN5d
First subject dosed in Cellarity’s trial of CLY-124 for sickle cell diseaseCellarity has dosed the first subject in a Phase I study of oral medication, CLY-124, to treat sickle cell disease (SCD).
6d
Healthshots on MSNLiving with Sickle Cell: What It Takes to Thrive, Not Just SurviveEven on stable days, people with SCD live with a range of complications: chronic anaemia, joint pain, slowed growth, ...
“We find that a lot of young people don’t pass the [fertility] test because you have to have an anti-mullerian hormone (AMH) level of about three and over nanograms per millilitre to be able to ...
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK ® (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic ...
Most people with SCD seem to meet or exceed current level of physical activity recommendations for the general population, a ...
Gene therapy for sickle cell disease may help improve a major contributing factor to stroke risk in patients, reports a new ...
The World Health Organization has released its first-ever global guideline on the management of sickle cell disease during ...
A doctor says she’s scrambling to figure out how she’ll continue her work helping sickle cell disease patients after the ...
Pune: Jyoti has seen her first-born go through regular blood transfusions due to her sickle cell and thalassaemia conditions. So she was fearful and h.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results